Perilous Reversal Stock: Amicus Therapeutics (FOLD)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Amicus Therapeutics ( FOLD) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Amicus Therapeutics as such a stock due to the following factors:

  • FOLD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $23.2 million.
  • FOLD has traded 178,235 shares today.
  • FOLD is down 3.6% today.
  • FOLD was up 20.4% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in FOLD with the Ticky from Trade-Ideas. See the FREE profile for FOLD NOW at Trade-Ideas

More details on FOLD:

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Currently there are 3 analysts that rate Amicus Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Amicus Therapeutics has been 1.8 million shares per day over the past 30 days. Amicus has a market cap of $358.1 million and is part of the health care sector and drugs industry. The stock has a beta of 1.76 and a short float of 8.1% with 0.31 days to cover. Shares are up 94.5% year-to-date as of the close of trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Remember, Fed News Is a Trigger for the Computers

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

The Flippers Are at Work and the Bears Are Hopeful

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

Time to Bring Amicus Therapeutics Into the 'FOLD'